Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 double-blinded, placebo-controlled, randomized, multinational study of Avigan (favipiravir) for the prevention of COVID-19

Trial Profile

Phase 3 double-blinded, placebo-controlled, randomized, multinational study of Avigan (favipiravir) for the prevention of COVID-19

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Favipiravir (Primary)
  • Indications COVID 2019 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms PEPCO
  • Sponsors Appili Therapeutics
  • Most Recent Events

    • 17 Jun 2021 According to an Appili Therapeutics media release, the company expects to initiate enrollment in the second half of 2021 following successful completion of the PRESECO study.
    • 08 Dec 2020 New trial record
    • 24 Nov 2020 According to a Appili Therapeutics media release, The PEPCO and PRESECO studies will be part of the dataset for the recently announced consortium to develop and distribute Avigan tablets globally in COVID-19 indications. The company may expand these trials into other countries severely affected by COVID, including those in Central and South America and the European Union.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top